INTRODUCTION {#s1}
============

Head and neck cancer (HNC) include tumors derived from any tissue or organ from the eyes, brain, ears, thyroid and esophageal head and neck, and over 90% of HNC are squamous cell carcinoma. The incidence of global head and neck squamous cell carcinoma (SCCHN) has increased significantly over the last 10 years, especially in women. There are about 645,000 new cases of HNC occurring each year. In 2002, the new cases of HNC was about 100800 cases in Europe, and cause more than 40,000 deaths \[[@R1]\]. The etiology of Head and neck cancer involves both genetic and environmental factors. Tobacco consumption and excessive alcohol drinking are independent major risk factors for HNC development \[[@R2]--[@R4]\]. Despite significant advances in multidisciplinary treatment, about 30--50% of HNC patients survived for 5 years \[[@R5], [@R6]\]. Therefore, further studies should be conducted to identify potential chemical precautions other than tobacco alcohol abstinence.

Non-steroidal antiinflammatory drugs NSAIDs (NSAIDs) have been widely used in clinical. Since the 1980s, NSAIDs have received widespread attention as anti-tumor properties. Such drugs include aspirin, acetaminophen, indomethacin, naproxen, naproxen, diclofenac, ibuprofen, nimesulide, rofecoxib and celecoxib. With anti-inflammatory, anti-rheumatic, pain, fever and anticoagulation and other effects, widely used in clinical osteoarthritis, rheumatoid arthritis, a variety of fever and various pain symptoms \[[@R7]\].

Previous studies have examined the relationship between NSAIDs use and risk of colon cancer, stomach cancer, prostate cancer and breast cancer, have found that NSAIDs use is significantly reduce cancer risk \[[@R8]--[@R11]\]. However, no study to clarify and quantitative assessed NSAIDs use in relation to HNC risk. Thus, we conducted this dose-response meta-analysis to clarify and quantitative assessed the relationship between NSAIDs use and HNC risk.

MATERIALS AND METHODS {#s2}
=====================

Our meta-analysis was conducted according to the Meta-analysis Of Observational Studies in Epidemiology (MOOSE) checklist \[[@R12]\].

Search strategy {#s2_1}
---------------

We included eligible studies investigating the relationship of NSAIDs using and HNC risk in general adult populations. To develop a flexible, non-linear, r meta-regression model, we required that an eligible study should have categorized NSAIDs duration into 3 or more levels. If multiple publications were available for a study, we included the longest follow-up study.

Eligible studies were systematically searched of PubMed and Embase update to March 2017 for case control or cohort studies examining the relationship between NSAIDs using and HNC risk, with keywords including "head and neck cancer" OR"HNC"OR "Oral" OR "Oropharynx" OR "hypopharynx" OR "larynx" AND "aspirin" OR "NSAIDs" OR "ibuprofen" OR "naproxen" OR "indomethacin" OR "meloxicam" OR "valdecoxib" OR "celecoxib" OR "rofecoxib". We refer to the relevant original essays and commentary articles to determine further relevant research. Eligible study was included through the reference lists of relevant review articles.

Study selection {#s2_2}
---------------

Two independent researchers investigate information the relationship between NSAIDs use and HNC risk: study design in case-control or cohort study; outcome was head and neck cancer; the relative risks at least three quantitative categories of NSAIDs use and head and neck cancer risk with 95% confidence intervals. Moreover, we precluded non-human studies, reviews, editorials and published letters. The disagreements were resolved through consensus by all of the authors.

Data extraction {#s2_3}
---------------

Use standardized data collection tables to extract data. The two researchers extracted detailed information from each included article. We extracted the following information: first author; publication year; age; country; sex; cases and participants; the categories of NSAIDs use; relative risk or odds ratio (OR) with 95% confidence intervals. We collect the risk estimates with multivariable-adjusted \[[@R13]\]. Quality assessment was performed according to the Newcastle-Ottawa scale for non-randomized studies \[[@R14]\].

Statistical analysis {#s2_4}
--------------------

We pooled relative risk estimates as the common measure of association NSAIDs use and head and neck cancer risk; the hazard ratio were considered equivalent to the relative risk \[[@R15]\]. Results in different subgroups of NSAIDs using and HNC risk were treated as two separate reports.

Due to different cut-off points in the included studies for categories, we performed a relative risk with 95% confidence interval by increase per 2 prescriptions/week using the method recommended by Greenland, Longnecker and Orsini and their colleagues. Dose of NSAIDs using used the median NSAIDs using. If the median NSAIDs using category was not available, the midpoint of the upper and lower boundaries was considered the dose of each category. The midpoint of the category was set at 1.5 times the lower boundary if the highest category was open ended. We use the midpoint of the category if the highest and lowest values are not reported. The midpoint of the category is estimated by assuming that the width of the category is the same as the next adjacent category if the highest or lowest category is open. In addition, we evaluated the non-linear association between NSAIDs using and head and neck cancer risk using restricted cubic splines, with three knots at the 10th, 50th, and 90th percentiles of the distribution. A flexible meta-regression based on restricted cubic spline (RCS) function was used to fit the potential non-linear trend, and generalized least-square method was used to estimate the parameters. This procedure treats nonsteroidal anti-inflammatory drugs using (continuous data) as an independent variable and logRR of diseases as a dependent variable, with both tails of the curve restricted to nonlinear. A *P* value is calculated for linear or non-linear by testing the null hypothesis that the coefficient of the second spline is equal to zero \[[@R16]\].

The between-study heterogeneity was assessed by Q-statistic and the I^2^-statistic. All analyses were conducted using STATA software 12.0 (STATA Corp, College Station, TX, USA). *P* \< 0.05 was considered significant for all tests.

RESULTS {#s3}
=======

Literature search results {#s3_1}
-------------------------

We identifed 3088 relevant citations after exclusion of duplicates. After exclusion studies that did not fulfill the inclusion criteria, eleven studies were chosen, and the data were extracted. Results in different subgroups of NSAIDs using and head and neck cancer risk were treated as two separate reports, a total of 33 reports data were included in this meta-analysis. These studies were published update to March 2017. Figure [1](#F1){ref-type="fig"} shows the results of literature research and selection.

![Flow diagram of the study selection process](oncotarget-08-99066-g001){#F1}

Study characteristics {#s3_2}
---------------------

The characteristics of the included studies of nonsteroidal anti-inflammatory drugs using and risk of head and neck cancer are shown in the Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}. Among the selected studies, four cohort studies \[[@R17]--[@R20]\] and seven case--control studies \[[@R6], [@R21]--[@R26]\], a total of 653828 participants with 12637 incident cases were included in this meta-analysis.

###### Characteristics of participants in included studies of nonsteroidal anti-inflammatory drugs using and risk of head and neck cancer

  Author (year)               Study name                                 Study design    Country     Sex of population   Age at baseline (years)   No of participants   No of cases   Quality score
  --------------------------- ------------------------------------------ --------------- ----------- ------------------- ------------------------- -------------------- ------------- ---------------
  Ahmadi et al. (2010)        The Lombardi Comprehensive Cancer Center   Case-control    USA         Mix                 56                        142                  71            5
  Becker et al. (2015)        CPRD                                       Case--control   UK          Mix                 \< 90                     19215                2745          7
  Bosetti et al. (2003)       NA                                         Case--control   Italy       Mix                 \> 25                     2744                 965           6
  Di et al. (2015)            NA                                         Case--control   Caucasian   Mix                 52                        790                  198           6
  Friis et al. (2006)         The Danish Civil Registration System       Cohort          Denmark     Mix                 \> 16                     442654               260           8
  Friis et al. (2003)         The Danish Civil Registration System       Cohort          Denmark     Mix                 \> 16                     29470                2187          8
  Jayaprakash et al. (2006)   The Roswell Park Cancer Institute          Case--control   USA         Mix                 40                        1058                 529           6
  Macfarlane et al. (2012)    The ARCAGE study                           Case--control   Europe      Mix                 \> 25                     3772                 1779          7
  Macfarlane et al. (2014)    PCCIU                                      Case--control   Scotland    Mix                 66                        9557                 2392          7
  Macfarlane et al. (2015)    PCCIU                                      Cohort          Scotland    Mix                 66                        2392                 1195          7
  Wilson et al. (2013)        The PLCO trial                             Cohort          USA         Mix                 55--74                    142034               316           7

CPRD: The UK-based Clinical Practice Research Datalink; ARCAGE: The Alcohol-Related CAncers and GEnetic Susceptibility; PCCIU: The Primary CareClinical Informatics Unit; The PLCO trial: The United States National Cancer Institute Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial

###### Outcomes and covariates of included studies of nonsteroidal anti-inflammatory drugs using and risk of head and neck cancer

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author (year)               Endpoints   Data source         Category and relative risk (95% CI)                                                                                                Covariates in fully adjusted model
  --------------------------- ----------- ------------------- ---------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Becker et al. (2015)                    Population-based    COX 2 inhibitors\                                                                                                                  Adjusted for all other medications in this table, Body mass index, smoking, and alcohol consumption
                                                              No prior use, 1.0 (reference);1 RX, 1.14 (0.89, 1.47); \> 2-- \< 5, 1.0 (0.73, 1.35); ; ≥ 6, 1.12 (0.81, 1.55)\                    
                                                              Diclofenac\                                                                                                                        
                                                              No prior use, 1.0 (reference);1 RX, 0.97 (0.86, 1.10); \> 2-- \< 5, 1.02 (0.89, 1.17); ; ≥ 6, 1.05 (0.89, 1.25)\                   
                                                              Ibuprofen\                                                                                                                         
                                                              No prior use, 1.0 (reference);1 RX, 1.00 (0.89, 1.12); \> 2-- \< 5, 0.94 (0.83, 1.08); ; ≥ 6, 0.78 (0.64, 0.96)\                   
                                                              Naproxen\                                                                                                                          
                                                              No prior use, 1.0 (reference);1 RX, 0.97 (0.81, 1.15); \> 2-- \< 5, 0.97 (0.72, 1.14); ; ≥ 6, 1.18 (0.88, 1.58)\                   
                                                              Other NSAIDs\                                                                                                                      
                                                              No prior use, 1.0 (reference);1 RX, 0.97 (0.81, 1.15); \> 2-- \< 5, 1.15 (0.95, 1.38); ; ≥ 6, 0.99 (0.80, 1.22)\                   
                                                              Aspirin\                                                                                                                           
                                                              No prior use, 1.0 (reference);1 RX, 1.10 (0.94, 1.28); \> 2-- \< 5, 1.02 (0.88, 1.18); ; ≥ 6, 1.21 (0.97, 1.51)                    

  Friis et al. (2006)                     Self-administered   Aspirin\                                                                                                                           Adjusted for age, sex
                                                              No prior use, 1.0 (reference); \> 2-- \< 9, 1.0 (0.6, 1.6); ; ≥ 10, 1.31 (1.0,1.6)                                                 

  Jayaprakash et al. (2006)               Population-based    Aspirin\                                                                                                                           Adjusted for age, sex, packs of cigarettes per day, and alcoholic drinks per week
                                                              No prior use, 1.0 (reference);1 RX, 0.68 (0.46, 1.02); \> 2-- \< 6, 1.08 (0.75, 1.54); ; ≥ 7, 0.68(0.47, 0.99)                     

  Macfarlane et al. (2012)                Population-based    Aspirin\                                                                                                                           Adjusted for centre, age, gender, education, smoking (pack-years), alcohol drinking (drink-years), fruit consumption and body mass index 2 years ago
                                                              No prior use, 1.0 (reference);1 RX, 0.98 (0.72, 1.34); \> 2-- \< 6, 0.80 (0.62, 1.04); ; ≥ 7, 0.96(0.75, 1.25)                     

  Macfarlane et al. (2014)                Self-administered   Aspirin\                                                                                                                           adjusted for deprivation, BMI (o25), smoking (ever), alcohol consumption (high), CHD, stroke
                                                              No prior use, 1.0 (reference); \> 0.4-- \< 4, 0.88 (0.70, 1.09); \> 5-- \< 7, 0.82 (0.67, 1.00); \> 8-- \< 40, 0.90 (0.75, 1.25)   

  Macfarlane et al. (2015)                Self-administered   Aspirin\                                                                                                                           Adjusted for age, gender, deprivation, year of diagnosis, smoking (ever), alcohol consumption (high), CHD, AF, Stroke, Aspirin ((before and after diagnosis), COX-2 (before and after diagnosis), other NSAID (before and after diagnosis) and taking into account clustering within medical practices.
                                                              No prior use, 1.0 (reference); \< 3, 0.81 (0.60, 1.09); \> 3-- \< 6, 0.48 (0.33, 0.71); \> 6, 0.55(0.36, 0.84)                     

  Wilson et al. (2013)                    Self-administered   Aspirin\                                                                                                                           Multivariate adjustments: age at baseline (years), gender, BMI (o18.5, 18.5--o25, 25--o30, X30 kg m 2), tobacco use (None, 40--29, 429--49, 449 maximum cigarette pack years); Ibuprofen model further adjusted for aspirin use
                                                              No prior use, 1.0 (reference); 1, 0.69 (0.51, 0.93); 7, 0.85 (0.65, 1.11)\                                                         
                                                              Ibuprofen\                                                                                                                         
                                                              No prior use, 1.0 (reference); 1, 1.03 (0.76, 1.39); 7, 0.86 (0.56, 1.32)                                                          
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Rx = prescription.

Overall meta-analysis {#s3_3}
---------------------

The results of NSAIDs using and HNC risk are shown in Table [3](#T3){ref-type="table"}. The pooled results suggest that NSAIDs using is significantly associated with head and neck cancer risk, which was suggested both by the highest NSAIDs using versus lowest NSAIDs using (RR:0.84; 95% CI, 0.76--0.93; *P* \< 0.001) (Table [3](#T3){ref-type="table"}). We found evidence of between-study heterogeneity (I^2^ = 70.5%, *P* = 0.000) but we observed no evidence of publication bias (Egger asymmetry test, *P* = 0.245) ([Supplementary Table 2](#SD1){ref-type="supplementary-material"}).

###### Stratified analyses of relative risk of head and neck cancer

                           No of reports   Relative risk (95% CI)   P for heterogeneity   I2      *P* for test
  ------------------------ --------------- ------------------------ --------------------- ------- --------------
  **Type of drugs use**                                                                           
  Total                    33              0.84 (0.76--0.93)        0.000                 70.5%   *P* \< 0.01
  Aspirin Use              22              0.85 (0.74--0.96)        0.000                 66.0%   *P* \< 0.01
  COX 2 inhibitors         3               0.79 (0.70--0.98)        0.357                 3.0%    *P* \< 0.01
  Ibuprofen                2               0.85 (0.69--0.97)        0.223                 32.8%   *P* \< 0.01
  Other NSAIDs             6               0.76 (0.59--0.94)        0.000                 88.2%   P \< 0.01
  **HNC sites**                                                                                   
  Oral and oropharynx      6               0.85 (0.77--0.94)        0.118                 43.0%   *P* \< 0.01
  Larynx                   3               0.76 (0.66--0.92)        0.155                 46.3%   *P* \< 0.01
  Hypopharynx              2               0.59 (0.27--0.91)        0.532                 0.0%    *P* \< 0.01
  **Study design**                                                                                
  Cohort                   8               0.85 (0.72--0.98)        0.000                 76.7%   *P* \< 0.01
  Case-control             25              0.83 (0.73--0.93)        0.000                 68.5%   *P* \< 0.01
  **No of participants**                                                                          
  ≥ 10 000                 11              0.82 (0.71--0.93)        0.014                 55.1%   *P* \< 0.01
  \< 10 000                22              0.74 (0.64--0.83)        0.000                 64.6%   *P* \< 0.01
  **No of cases**                                                                                 
  ≥ 500                    28              0.84 (0.75--0.93)        0.000                 70.0%   *P* \< 0.01
  \< 500                   5               0.76 (0.58--0.98)        0.001                 77.9%   *P* \< 0.01
  **Study quality**                                                                               
  Score ≥ 7                23              0.91 (0.83--0.99)        0.000                 64.9%   *P* \< 0.01
  Score \< 7               10              0.60 (0.40--0.80)        0.002                 65.5%   *P* \< 0.01

*P* for test: The test for highest versus lowest meta-analysis on drugs use and head and neck cancer risk.

Dose--response meta-analyses between NSAIDs using and head and neck cancer {#s3_4}
--------------------------------------------------------------------------

Using restricted cubic spline function, the test for a nonlinear dose-response relationship was significant (likelihood ratio test, *P* = 0.000), suggesting curvature in the relationship, increase per 2 prescriptions/week of NSAIDs using was associated with a 4% decremental in head and neck cancer risk, the summary relative risk of head and neck cancer risk for an increase per 2 prescriptions/week of NSAIDs using was 0.96 (95% CI: 0.94--0.99, *P* \< 0.001) (Figure [2](#F2){ref-type="fig"}). Increasing aspirin using (per 2 prescriptions/week increment) was related to a 5% reduction in head and neck cancer risk (RR: 0.95; 95% CI, 0.91--0.99) (Figure [3](#F3){ref-type="fig"}). Increasing other NSAIDs using (per 2 prescriptions/week increment) was related to a 6% reduction in head and neck cancer risk (RR: 0.94; 95% CI, 0.89--0.96) (Figure [4](#F4){ref-type="fig"}).

![Dose-response relationship between NSAIDs using and head and neck cancer\
(The solid line represents fitted non-linear trend, the dotted line represents the 95% confdence interval).](oncotarget-08-99066-g002){#F2}

![Dose-response relationship between aspirin using and head and neck cancer\
(The solid line represents fitted non-linear trend, the dotted line represents the 95% confdence interval).](oncotarget-08-99066-g003){#F3}

![Dose-response relationship between other NSAIDs using and head and neck cancer\
(The solid line represents fitted non-linear trend, the dotted line represents the 95% confdence interval).](oncotarget-08-99066-g004){#F4}

Subgroup analyses {#s3_5}
-----------------

Subgroup analysis was performed to check the stability of the primary outcome (Table [3](#T3){ref-type="table"}). Subgroups analysis indicated that Aspirin (RR:0.85; 95% CI, 0.74--0.96; *P* \< .001) (Table [3](#T3){ref-type="table"}), COX 2 inhibitors (RR:0.79; 95% CI, 0.70--0.98; *P* \< .001) (Table [3](#T3){ref-type="table"}), Ibuprofen(RR:0.85; 95% CI, 0.69--0.97; *P* \< .001) (Table [3](#T3){ref-type="table"}) and Other NSAIDs (RR:0.76; 95% CI, 0.59--0.94; *P* \< .001) (Table [3](#T3){ref-type="table"}) were associated with a significantly risk of head and neck cancer. Furthermore, nonsteroidal anti-inflammatory drugs using was associated with a significantly lower risk of Oral and oropharynx cancer (RR:0.85; 95% CI, 0.77--0.94; *P* \< .001) (Table [3](#T3){ref-type="table"}), Larynx cancer (RR:0.76; 95% CI, 0.66--0.92; *P* \< .001) (Table [3](#T3){ref-type="table"}) and Hypopharynx cancer (RR:0.59; 95% CI, 0.27--0.91; *P* \< .001) (Table [3](#T3){ref-type="table"}).

Sensitivity analysis {#s3_6}
--------------------

A sensitivity analysis omitting 1 study at a time and calculating the pooled ORs for the remainder of the studies showed that 2 studies by Becker et al. (2015) \[[@R22]\] and Macfarlane et al. (2012) \[[@R25]\] substantially influenced the pooled OR. After excluding the 2 studies, there was no study heterogeneity (PQ = 0.965, I^2^ = 0.0%), and the OR for the highest vs lowest category of NSAIDs using was 0.83 (95% CI, 0.75--0.96) ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}).

Publication bias {#s3_7}
----------------

The results show no obvious evidence of publication bias was found in the associations between NSAIDs using and head and neck cancer risk ([Supplementary Table 2](#SD1){ref-type="supplementary-material"}).

DISCUSSION {#s4}
==========

NSAIDs as antipyretic analgesic anti-inflammatory drugs have been widely used in clinical, especially in the prevention and treatment of cardiovascular disease. Since the 80s of last century, NSAIDs anti-tumor properties have been widespread concern. Vinogradova found that long-term using of NSAIDs and cyclooxygenase-2 (COX-2) inhibitors can reduce the risk of developing colorectal cancer through a large sample of clinical case-control analysis \[[@R27]\]. Another study shows that NSAIDs can reduce the incidence of colonic adenoma and postoperative recurrence rate \[[@R28], [@R29]\]. Moreover, NSAIDs can reduce esophageal cancer, endometrial cancer, ovarian cancer, prostate cancer, bladder cancer, malignant melanoma, skin cancer and other malignant tumors risk \[[@R30]--[@R36]\], but since then, studies of NSAIDs in head and neck cancer increased slowly.

Among the eleven included studies, eight showed a signifcantly positive association between NSAIDs using and head and neck cancer risk, and have found that NSAIDs use is significantly reduce head and neck cancer risk, while the other were negative. Studies on different NSAIDs using and head and neck cancer risk also remain inconclusive in light of newer evidence.

To our knowledge, this is the first study to identify and quantify the potential dose-response association between NSAIDs using and head and neck cancer in a large cohort of both men and women. The primary finding in our meta-analysis is that statistically significant association between nonsteroidal anti-inflammatory drugs using and head and neck cancer. Subgroups analysis indicated that Aspirin, COX 2 inhibitors, Ibuprofen and Other NSAIDs using were associated with a significantly risk of head and neck cancer. Furthermore, nonsteroidal anti-inflammatory drugs using was associated with a significantly lower risk in oral and oropharynx cancer, larynx cancer and hypopharynx cancer. In addition, increasing nonsteroidal anti-inflammatory drugs using (per 2 prescriptions/week increment) was associated with a 4% reduction in head and neck cancer risk, 5% reduction of aspirin using and 6% reduction of other nonsteroidal anti-inflammatory drugs using.

Although, we performed this meta-analysis very carefully, some limitations must be considered in the current meta-analysis. Firstly, different sex of population should be included in this meta-analysis to explore the impact of different sex of population on nonsteroidal anti-inflammatory drugs using and head and neck cancer. Secondly, despite we searched all studies describing the association between NSAIDs using and HNC risk, there are only 11 studies about NSAIDs using and HNC risk, the number of eligible studies was still limited.

In conclusion, our meta-analysis suggests NSAIDs using was independently associated with deleterious head and neck cancer risk reduction. However, more studies and large sample size are warranted to validate this association.

SUPPLEMENTARY MATERIALS FIGURES AND TABLES {#s5}
==========================================
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